Cepheid Receives FDA Clearance To Market Xpert Carba-R - Quick Facts

(RTTNews) - Cepheid (CPHD) announced it has received clearance from the U.S. FDA to market Xpert Carba-R, a qualitative in vitro diagnostic test for reproducible identification of 5 distinct families of carbapenem resistance genes. Xpert Carba-R is the latest diagnostic solution from Cepheid to help infection control professionals fight antimicrobial resistance. The product will begin shipping later in March.

Cepheid said Xpert Carba-R is the first FDA-cleared test for detection and differentiation of carbapenemase genes in pure bacterial isolates, previously shown to be non-susceptible to carbapenem antibiotics, which may be cultured from a wide range of clinical specimens, including blood cultures, urine, respiratory samples, abscesses and swab surveillance specimens.